Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

6 results
Display

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis

Kamimura M, Ikegami S, Mukaiyama , Koiwai H, Nakamura Y, Taguchi A, Kato H

OBJECTIVES: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of patient background factors on the treatment efficacy of once-weekly teriparatide

Omura F

OBJECTIVES: The impact of patient background factors on changes in bone mineral density (BMD) and bone metabolic markers after treatment with once-weekly teriparatide (W-TPTD) has not been fully elucidated. To...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk

Ifuku E, Yoshimura , Uzawa T, Hokonohara T

OBJECTIVES: To reassess the safety and efficacy of once-weekly teriparatide 56.5 mg in osteoporosis patients with a high fracture risk. METHODS: This postmarketing observational study was conducted at 72 weeks according...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The incidence of hip fracture and mortality rate after hip fracture in Korea: A nationwide population-based cohort study

Hong S, Han K

OBJECTIVES: Osteoporotic hip fractures are associated with high mortality in the older population. Few population studies have reported the long-term trends of incidence and mortality rate of hip fracture among...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diabetes and bone

Hygum K, Starup-Linde J, Langdahl B

Bone disease is a serious complication to diabetes. Patients with type 1 diabetes (T1D) and type 2 diabetes (T2D) suffer from an increased risk of fracture, most notably at the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How different is the once-weekly teriparatide from the daily one or the same?

Takeuchia

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr